Baird Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $47

Benzinga · 12/30/2025 17:54
Baird analyst Joel Beatty maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and lowers the price target from $72 to $47.